Heidi Expands to Singapore With $8 Million Investment to Scale AI Medical Scribe Across Asia

Australian healthtech company Heidi, known for its AI-powered medical scribe platform, has expanded into Singapore with plans to invest $8 million over the next three years to establish a regional hub and accelerate adoption across Southeast Asia. The move marks a significant milestone for the Melbourne-based startup, which has grown rapidly following its US$65 million Series B funding round.

The Singapore expansion positions Heidi to tap into one of the world’s most advanced healthcare ecosystems, one that has invested heavily in digital transformation, interoperability and clinician-support technologies.

A Strategic Expansion Backed by Strong Funding Momentum

Heidi’s entry into Singapore comes on the heels of its substantial Series B raise, led by global investors backing the company’s plan to modernise clinical documentation and AI-driven care workflows. With the new investment, Heidi will build out local engineering, clinical success and customer deployment teams to support hospitals, specialist networks and primary-care providers in the region.

The company’s leadership, CEO Dr. Tom Kelly, CFO Waleed Mussa and CTO Yu Liu, have described Singapore as a natural springboard for global expansion due to its strong regulatory frameworks, thriving healthtech ecosystem and central role in Asia-Pacific healthcare innovation. “Heidi’s mission has always been to give clinicians back their time,” Kelly has said in previous statements. “Singapore offers the ideal environment to scale this mission across Asia.”

Why Is Singapore the Gateway to Asia for AI-Driven Healthcare ?

Singapore’s healthcare market is undergoing a rapid digital shift, driven by rising care demand, clinician shortages and administrative overload. Hospitals across the region have prioritised technology that reduces documentation burden and improves clinical efficiency.

This landscape makes Singapore a strategic base for Heidi’s AI scribe technology, which automates the generation of clinical notes, referral letters and task workflows from patient encounters. By integrating directly into electronic medical record (EMR) systems, Heidi removes hours of daily administrative work for physicians, an issue that has become a critical strain point across both public and private healthcare.

Singapore’s strong demand for digital health adoption and interoperability between care settings aligns directly with Heidi’s value proposition. Its expansion also positions the company to engage with Southeast Asia’s largest and fastest-growing healthcare markets, including Malaysia, Indonesia, Thailand and the Philippines.

A Product Built for Clinicians, Designed to Scale Globally

Heidi’s platform functions as an “AI medical scribe”, capturing clinical consultations and automatically generating structured documentation tailored to each specialty and clinician style. Unlike generic transcription tools, Heidi’s system creates complete, actionable notes that integrate seamlessly into clinical workflows.

The company now supports clinicians across more than 100 countries, offering custom templates, automated follow-up tasks, real-time updating and deep EMR integrations. For health systems struggling with clinician burnout and rising patient loads, the technology directly addresses one of the biggest operational barriers: documentation takes up to 40% of a clinician’s day. This scalability was a central factor behind Heidi’s decision to plant its APAC headquarters in Singapore. The regional hub will serve as the centre for deploying Heidi’s AI Care Partner technology across hospitals, clinic networks, aged-care groups and telehealth providers throughout Asia.

Addressing Southeast Asia’s Clinician Shortage and Administrative Burden

Southeast Asian healthcare systems are under pressure. Rising patient volumes, workforce shortages and chronic under-documentation create significant operational bottlenecks. Clinicians increasingly spend evenings and weekends completing notes, reducing morale and spiking burnout rates across the region.

Heidi’s AI-powered scribe aims to reverse those trends by eliminating after-hours paperwork and enabling clinicians to spend more time with patients. The company’s early deployments in Australia have shown strong reductions in administrative workload, faster clinical note completion and higher satisfaction among physicians.

By bringing the platform to Singapore and Southeast Asia, Heidi positions itself to become a critical component of the region’s healthcare digitalisation efforts.

Building the Infrastructure Layer for AI-Enabled Clinical Workflows

Heidi’s expansion is not just about entering a new geography, it represents a broader move to establish itself as the infrastructure layer for AI-enabled clinical workflows worldwide. As more countries and health systems adopt AI-first strategies, companies that can support seamless, clinician-friendly documentation will play central roles in healthcare modernisation. The $8M Singapore investment will be used for:

• Expanding commercial partnerships across Asia
• Scaling AI engineering and R&D
• Deploying enterprise-grade AI scribe solutions to hospitals
• Adapting Heidi’s platform to local regulatory and clinical environments
• Building out local customer and technical support teams

With its APAC hub established, Heidi will be positioned to compete in one of the world’s fastest-growing digital health regions.

A Future Where AI Reduces Administrative Load Across Borders

As global health systems continue to digitise, demand for clinical workflow automation is rising rapidly. Heidi’s expansion into Singapore signals its ambition to become a leading global player in AI-powered healthcare operations.

By combining strong clinical leadership, sophisticated AI technology and a strategic regional base, Heidi is charting a path toward becoming an essential tool for physicians across Asia and a major force in the next generation of healthcare software.

Heidi’s expansion into Singapore reflects a timely move in a region where clinician shortages and administrative overload are becoming unsustainable. The company’s AI medical scribe technology clearly addresses a real and growing pain point and Singapore offers the ideal environment to scale such solutions responsibly.

However, the true measure of Heidi’s impact will depend on its ability to deliver consistent, specialty-grade accuracy across diverse clinical settings in Asia, an ecosystem far more varied than Australia. If it succeeds, Heidi could emerge as one of the most influential healthtech players driving AI-enabled clinical efficiency across the region.